Fatores associados com a escolha da terapia nos pacientes com doença inflamatória intestinal no Brasil / Factors associated with patient´s preference in choosing their therapy for inflammatory bowel disease in brazil

BACKGROUND: Biological therapy and new drugs have revolutionized the treatment of inflammatory bowel disease. Ideally, the choice of medication should be a shared decision with the patient, aiming at greater satisfaction, compliance, and consequently, favorable clinical outcome. OBJECTIVE: This study aims to evaluate patient's preferences in the choice of their therapy and the factors that influence this choice. METHODS: This cross-sectional study enrolled 101 outpatients with Crohn's disease or ulcerative colitis. The inclusion criteria were age ≥18 years and no previous exposure to biological therapy. Patients' preferences were assessed through questions that addressed the preferred mode of administration (oral, subcutaneous, or intravenous) and the factors that determined the choice of medication (efficacy, medical indication, fear of medication, convenience, mode of application, and personal doctors' indication). RESULTS: The mean age was 43.6±13.5 years, 75.3% were female, and 81.2% were cases of ulcerative colitis. Regarding the mode of administration, the majority of patients preferred oral (87.1%), followed by intravenous (6.93%) and subcutaneous (5.94%) medications. The reasons were "I prefer to take it at home" (42.57%), "I have more freedom" (36.63%), "I don't like self-application" (29.70%), and "I believe it works better" (19.80%). Younger patients and patients in clinical disease activity preferred intravenous mode compared to the oral route (P<0.05). Doctor's opinion (98%) was an important factor associated with the medication choice. CONCLUSION: Oral route was the preferred mode of administration and most patients took their physician's opinion into account in their choice of medication.

RESUMO CONTEXTO: A terapia biológica e os novos medicamentos revolucionaram o tratamento da doença inflamatória intestinal. A escolha do medicamento deve ser compartilhada com o paciente, visando maior satisfação, adesão e, consequentemente, desfecho clínico favorável. OBJETIVO: Este estudo teve como objetivo avaliar as preferências do paciente na escolha de sua terapia e os fatores que influenciaram essa escolha. MÉTODOS: Este estudo transversal incluiu 101 pacientes ambulatoriais com doença de Crohn ou retocolite ulcerativa. Os critérios de inclusão foram idade ≥18 anos e nenhuma exposição prévia à terapia biológica. A preferência dos pacientes foi avaliada por meio de perguntas que abordaram o modo de administração preferido (oral, subcutâneo ou intravenoso) e os fatores que determinaram a escolha do medicamento (eficácia, indicação médica, medo da injeção, conveniência, modo de aplicação e opinião pessoal do médico). RESULTADOS: A idade média foi de 43,6±13,5 anos, 75,3% eram mulheres e 81,2% eram portadores de retocolite ulcerativa. Em relação ao modo de administração, a maioria dos pacientes preferiu os medicamentos orais (87,1%), seguidos dos endovenosos (6,93%) e subcutâneos (5,94%). Os motivos foram "prefiro aplicar em casa" (42,57%), "tenho mais liberdade com essa medicação" (36,63%), "não gosto de autoaplicação" (29,70%) e "acredito que funcione melhor" (19,80%). Pacientes jovens e pacientes em atividade clínica preferiram a via intravenosa em comparação com a via oral (P<0,05). A opinião do médico (98%) foi um fator importante associado à escolha do medicamento. CONCLUSÃO: A via oral foi preferida e a maioria dos pacientes levou em consideração a opinião do seu médico na escolha do medicamento.

Revisión con aguja asociada a mitomicina C en ampollas de filtración encapsuladas / Mitomycin C-associated needle revision in encapsulated filtering blebs

Objetivo: determinar la efectividad a mediano plazo de la revisión con aguja asociada a mitomicina C en la ampolla de filtración encapsulada postrabeculectomía. Métodos: estudio observacional descriptivo, prospectivo de serie de casos (30 ojos, 30 pacientes), con antecedentes de quiste de Tenon a corto plazo postrabeculectomía (1 mes-1 año). Se realizó revisión con aguja asociada a inyección subconjuntival MMC 0,01 % hasta completar 3 dosis en días alternos. Se evaluaron la presión intraocular y el uso de colirios hipotensores preoperatorio y posoperatorio a la semana, 1 mes, 3 meses, 1 año y 2 años. Se definió éxito si la presión intraocular era menor de 21 mmHg sin colirio hipotensor (éxito total) y con colirios hipotensores (éxito parcial). Se registraron las complicaciones quirúrgicas. Resultados: hubo descenso significativo de la presión intraocular media preoperatoria de 27,06 ± 5,2 mmHg a 13,10 ± 3,65 mmHg, 14,83 ± 3,68 mmHg y 16,70 ± 3,38 mmHg a la semana, 1 y 3 meses posoperatorios respectivamente, y se mantuvo estable hasta 2 años (16,70 ± 2,18 mmHg); p< 0,001 para cada comparación preoperatorio vs. posoperatorio), lo que representó una reducción de la presión intraocular del 51,8 por ciento a la semana; 44,4 por ciento al mes y 37 por ciento hasta los 2 años. La media del número de colirios hipotensores se redujo significativamente de 2,0 ± 0,0 (preoperatorio) a 0,4 ± 0,0 (2 años posoperatorios), p< 0,001. El éxito fue total en el 70 por ciento de los casos y parcial en el 30 por ciento, tras 2 años posoperatorios. Las complicaciones fueron: hemorragia subconjuntival (100 por ciento de casos), atalamia (40 por ciento) y Seidel positivo (26,7 por ciento). Conclusiones: la revisión con aguja asociada a mitomicina C subconjuntival como tratamiento de la ampolla encapsulada, logra reducción del 37 por ciento de la presión intraocular durante los dos primeros años posoperatorios con un mínimo de complicaciones(AU)

Objective: to determine the medium-term effectiveness of subconjuntival mitomicyn-C associated to needle revision on encapsulated filtering bleb after trabeculectomy. Methods: prospective, descriptive and observational case series study (30 eyes, 30 patients) with a history of Tenon cyst after short term trabeculectomy (1month-1year). These patients underwent needle revision associated to subconjuntival 0,01 percent mitomycin injection to completing three doses in every other day. The intraocular pressure and the use of hypotensive drops preoperatively and postoperatively were evaluated seven days, one month, three months, one year and two years after the procedure. The success of intervention was defined as total when the intraocular pressure was less than 21mmHg without hypotensive drops and partial with hypotensive drops. Surgical complications were recorded. Results: the mean preoperative intraocular pressure decreased significantly from 27,06 ± 5,2 mmHg to 13,10 ± 3,3 mmHg, 14,83 ± 3,68 mmHg and 16,70 ± 3,38 mmHg one week, one month and three months after surgery and remained stable (16,70 ± 2,18 mmHg) for 2 years, p< 0,001 for each preoperative and postoperative comparison; this represented an intraocular pressure reduction of 51,8 percent; 44,4 percent and 37 percent after one week, one month, and up to 2 years, respectively. The mean number of hypotensive drops lowered significantly from 2,0 ± 0,0 (preoperative) to 0,4 ± 0,0 (two years after surgery), being p< 0,001. Total success was attained in 70 percent of cases and partial in 30 percent after 2 years. Surgical complications were subconjuntival haemorrhage (in all patients), atalamy (40 percent) and positive Seidel index (26,7 percent). Conclusion: subconjuntival mitomicyn-C injection-associated needle revision for encapsulated bleb reduces intraocular pressure by 37 percent during the first 2 years after the procedure with minimal complications(AU)